Muromonab-cd3 (orthoclone okt3®), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation

ABSTRACT We report the results of a prospective non-randomized phase II study of Muromonab-CD3 (Orthoclone OKT3®), an anti-CD3 monoclonal antibody, with methylprednisolone (MP) and

cyclosporine (CSA) for acute GVHD (aGVHD) prophylaxis in 22 hematologic malignancy patients. OKT3 was given at 0.1 mg/kg/day with a maximum dose of 5 mg/day. Initial MP dose was 1000 mg

before OKT3, with subsequent doses at 1 mg/kg/day before each OKT3 infusion with a planned taper beginning at day +28. CSA (3 mg/kg/day) was given as a continuous infusion at day −1 and

adjusted to maintain serum levels between 250 and 399 ng/ml. Allogeneic BMT donors were HLA-matched siblings (_n_=17), single HLA-mismatched-related (_n_=1) and HLA-matched unrelated

(_n_=4). All patients achieved neutrophil engraftment at a median 11 days (range, 8–25 days). By intent-to-treat, the cumulative incidence of grade II–IV aGVHD was 33% (95% CI 13–53%) at a

median 26 days post-BMT (range, 14–84 days). Chronic GVHD developed in 11/12 evaluable patients. Eight patients (36%) developed OKT3 first dose reactions; no cases of post-transplant

lymphoproliferative disorder were observed. OKT3 depleted peripheral CD3+ cells _in vivo_ as measured by flow cytometry. OKT3+MP+CSA combination is moderately effective aGVHD prophylaxis,

however, it is unlikely to be superior to CSA+MTX. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS

Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on

SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about

institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS POST-TRANSPLANT CYCLOPHOSPHAMIDE, CALCINEURIN INHIBITOR, AND MYCOPHENOLATE

MOFETIL COMPARED TO ANTI-THYMOCYTE GLOBULIN, CALCINEURIN INHIBITOR, AND METHOTREXATE COMBINATIONS AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS POST ALLOGENEIC STEM CELL TRANSPLANTATION FROM

SIBLING AND UNRELATED DONORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: A STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION

Article 13 April 2024 COMPARISON OF MYCOPHENOLATE MOFETIL AND CALCINEURIN INHIBITOR VERSUS CALCINEURIN INHIBITOR-BASED GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS FOR MATCHED UNRELATED DONOR

TRANSPLANT IN ACUTE MYELOID LEUKEMIA. A STUDY FROM THE ALWP OF THE EBMT Article 28 November 2020 LOW-DOSE ANTITHYMOCYTE GLOBULIN PLUS LOW-DOSE POSTTRANSPLANT CYCLOPHOSPHAMIDE COMBINED WITH

CYCLOSPORINE AND MYCOPHENOLATE MOFETIL FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AFTER HLA-MATCHED UNRELATED DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION Article Open access 25 May

2021 REFERENCES * Cosimi AB . Clinical development of orthoclone OKT3. _Transplant Proc_ 1987; 14 (Suppl 1): 7–16. Google Scholar  * Hooks MA, Wade CS, Millikan WJ . Muromonab CD-3: a review

of its pharmacology, pharmacokinetics and clinical use in transplantation. _Pharmacotherapy_ 1991; 11: 26–37. CAS  PubMed  Google Scholar  * Hong JC, Kahan BD . Immunosuppressive agents in

organ transplantation: past, present, and future. _Semin Nephrol_ 2000; 20: 108–125. CAS  PubMed  Google Scholar  * Gleixner B, Kolb HJ, Holler E, Liesenfeld S, Riedner C, Hiller E _et al_.

Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNFa. _Bone Marrow Transplant_ 1991; 8: 93–98. CAS  PubMed  Google Scholar  * Gratama JW, Jansen J,

Filipovich RA, Tanke HJ, Goldstein G, Zwann FE . Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. _Transplantation_ 1984; 38: 469–474. Article  CAS  PubMed 

Google Scholar  * Martin PJ, Hansen JA, Anasetti C, Zutter M, Durnam D, Storb R _et al_. Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies. _Am J Kidney Dis_

1988; 11: 149–152. Article  CAS  PubMed  Google Scholar  * Hebart H, Ehninger G, Schmidt H, Berner B, Reuss-Borst M, Waller HD _et al_. Treatment of steroid-resistant acute graft-versus-host

disease after allogeneic bone marrow transplantation with anti-CD3/TcR monoclonal antibodies. _Bone Marrow Transplant_ 1995; 15: 891–894. CAS  PubMed  Google Scholar  * Filipovich AH,

Krawczak CL, Kersey JH, McGlave P, Ramsay NK, Goldman A _et al_. Graft-vs.host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone

marrow transplantation. _Br J Haematol_ 1985; 60: 143–152. Article  CAS  PubMed  Google Scholar  * Brown RA, Wolff SN, Fay JW, Pineiro L, Collins Jr RH, Lynch JP _et al_. High-dose

etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North

American Marrow Transplant Group. _Blood_ 1995; 85: 1391–1395. CAS  PubMed  Google Scholar  * Alidina A, Lawrence D, Ford LA, Baer MR, Bambach B, Bernstein SH _et al_. Thiotepa-associated

cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. _Biol Blood Marrow Transplant_ 1999; 5: 322–327. Article  CAS  PubMed  Google

Scholar  * Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB _et al_. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and

cyclophosphamide. _N Engl J Med_ 1983; 309: 1347–1353. Article  CAS  PubMed  Google Scholar  * Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C _et al_. Melphalan and purine

analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. _Blood_ 2001; 97:

631–637. CAS  PubMed  Google Scholar  * Stewart CC, Stewart SJ . Multiparameter data acquisition and analysis of leukocytes by flow cytometry. In: Darzynkiewicz Z, Robinson JP, Crissman HA

(eds). _Methods of Cell Biology_, Vol. 64. Academic Press, Inc.: New York, 2001, pp 289–312. Google Scholar  * Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA _et al_.

Regimen related toxicity in patients undergoing bone marrow transplantation. _J Clin Oncol_ 1988; 6: 1562–1568. Article  CAS  PubMed  Google Scholar  * Glucksberg H, Storb R, Fefer A,

Buckner CD, Neiman PE, Clift RA _et al_. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A matched sibling donors. _Transplantation_ 1974; 18:

295–304. Article  CAS  PubMed  Google Scholar  * Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W _et al_. Methotrexate and cyclosporine compared with cyclosporine alone for

prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. _N Engl J Med_ 1986; 314: 729–735. Article  CAS  PubMed  Google Scholar  * Hahn T, McCarthy PL,

Zhang MJ, Sobocinski K, Barrett AJ, Ringden O _et al_. Risk factors for acute GVHD after related HLA-matched allogeneic blood or marrow transplant. _Proc AACR_ 2006; 47, Abstract #2881. *

Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D _et al_. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine

for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. _Blood_ 1998; 92: 2303–2314. CAS  PubMed  Google Scholar  * Filipovich AH, McGlave PB,

Ramsay NK, Goldstein G, Warkentin PI, Kesey JH . Pretreatment of donor bone marrow with monoclonal antibody OKT-3 for prevention of acute graft-versus-host disease in histocompatible bone

marrow transplantation. _Lancet_ 1982; 1: 1266–1269. Article  CAS  PubMed  Google Scholar  * Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P _et al_. A phase II

multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. _Biol Blood Marrow Transplant_ 2005; 11: 465–471. Article  CAS 

PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS This study was supported by Ortho-Biotech Clinical Affairs, LLC. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of

Medical Oncology, Gazi University Medical School, Ankara, Turkey M Benekli * Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA T Hahn, B T Williams, M Cooper, H N Roy 

& P L McCarthy Jr * Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA P Wallace & C Stewart * Department of Pediatrics, Roswell Park

Cancer Institute, Buffalo, NY, USA B Bambach Authors * M Benekli View author publications You can also search for this author inPubMed Google Scholar * T Hahn View author publications You

can also search for this author inPubMed Google Scholar * B T Williams View author publications You can also search for this author inPubMed Google Scholar * M Cooper View author

publications You can also search for this author inPubMed Google Scholar * H N Roy View author publications You can also search for this author inPubMed Google Scholar * P Wallace View

author publications You can also search for this author inPubMed Google Scholar * C Stewart View author publications You can also search for this author inPubMed Google Scholar * B Bambach

View author publications You can also search for this author inPubMed Google Scholar * P L McCarthy Jr View author publications You can also search for this author inPubMed Google Scholar

CORRESPONDING AUTHOR Correspondence to P L McCarthy Jr. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Benekli, M., Hahn, T., Williams, B. _et al._

Muromonab-CD3 (Orthoclone OKT3®), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation. _Bone Marrow Transplant_ 38,

365–370 (2006). https://doi.org/10.1038/sj.bmt.1705450 Download citation * Received: 02 May 2006 * Revised: 21 June 2006 * Accepted: 23 June 2006 * Published: 24 July 2006 * Issue Date: 01

September 2006 * DOI: https://doi.org/10.1038/sj.bmt.1705450 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * OKT3 * monoclonal antibody * GVHD

prophylaxis * allogeneic BMT